Citi Sticks to Its Hold Rating for Novartis AG (NOVN)
Goldman Sachs Remains a Hold on Novartis AG (NOVN)
Novartis AG: Hold Rating Justified Amid Kisqali's Market Potential and FDA Approval
Buy Rating Affirmed: Novartis AG's Strong Growth Outlook and Underestimated Pipeline Potential
Novartis AG (NOVN) Receives a Buy From UBS
Novartis Lower as BofA Downgrades on Risks to Valuation
Novartis Cut to Neutral From Buy by B of A Securities
Novartis Analyst Ratings
BofA Securities Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $130
BMO Capital Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $118
Erste Group Maintains Novartis AG(NVS.US) With Buy Rating
Novartis Cut to Neutral From Buy by Goldman Sachs
Novartis Analyst Ratings
Goldman Sachs Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $121
Novartis Target Cut to $105 From $110 by Jefferies
Jefferies Downgrades Novartis AG(NVS.US) to Hold Rating, Raises Target Price to $123.5
Novartis AG (NOVN) Receives a Buy From Kepler Capital
Berenberg Raises Price Target on Novartis to CHF86 From CHF77, Maintains Hold Rating
Novartis AG (NOVN) Gets a Hold From Berenberg Bank
Analysts' Opinions Are Mixed on These Healthcare Stocks: Novartis AG (Six Swiss: CH:NOVN), Biogen (BIIB) and Sartorius (GB:0NIR)